Neuropathic Facial Pain

September 14, 2015

Vernalis released results of a phase II study of V158866 for neuropathic pain as a result of spinal cord injury. In the randomized, double-blind, placebo-controlled, two-period cross-over study, although dosing of V158866 resulted in elevated endocannabinoid levels, on an intent-to-treat basis the study failed to meet its pain reduction primary endpoint. Treatment with V158866 did show a trend toward efficacy on a per protocol basis (p=0.054) and was generally well-tolerated.

Related Medical Areas